Cardiovascular Group Rallies for Better Access Policies
Health plans across the country are rejecting prescriptions for cholesterol-lowering PCSK9 inhibitors at an average rate of 43 percent. And now one patient advocacy group has a message: Enough is enough.
Health Plan Report Cards Reveal High Rejection Rate for Cholesterol Meds
Rejection is never pleasant. But for the 34,459 patients whose health plans refuse to cover advanced treatment for high cholesterol, it could also be deadly.
Trials Data Strengthens Patients’ Demands for Breakthrough Cholesterol Meds
New data on PCSK9 inhibitors is in – and it may bolster patients’ demands for the breakthrough cholesterol drugs in the face of health plan coverage barriers.
“Accessing Cholesterol Treatments” is No Simple Task, Explains New Video
On the heels of recent research confirming breakthrough drugs’ impact on patients with high cholesterol, the Partnership to Advance Cardiovascular Health has released a quick-draw video exploring obstacles for patient access.
Will New Evidence on PCSK9 Inhibitors Improve Patient Access?
For patients with extremely high cholesterol, the promise of new PCSK9 inhibitors just keeps growing.
